These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1847 related items for PubMed ID: 31835042

  • 1. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW.
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [Abstract] [Full Text] [Related]

  • 2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 3. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A, Sharma S, Brar Z, Kumar V, Kumar A, Katara R, Mohanty SK.
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [Abstract] [Full Text] [Related]

  • 4. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [Abstract] [Full Text] [Related]

  • 5. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [Abstract] [Full Text] [Related]

  • 6. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 7. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y, Dong Y, Zhao R, Zhang B, Wang S, Zhang L, Hu M, He Q, Zhang W, Han B.
    Clin Lung Cancer; 2020 Sep 26; 21(5):e355-e362. PubMed ID: 32139332
    [Abstract] [Full Text] [Related]

  • 8. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
    El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Boustany Y, Benmokhtar S, Lamrani Alaoui H, El Annaz H, Abi R, Tagajdid MR, El Kochri S, El Mchichi B, Bouaiti EA, Lahlou IA, El Hassani RA, Ennibi K.
    Technol Cancer Res Treat; 2024 Sep 26; 23():15330338241288907. PubMed ID: 39363851
    [Abstract] [Full Text] [Related]

  • 9. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J, Liu Y.
    Pathol Res Pract; 2020 Feb 26; 216(2):152797. PubMed ID: 31926773
    [Abstract] [Full Text] [Related]

  • 10. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, Dingemans AMC, Lolkema MP, Paats MS, Dubbink HJ.
    Lung Cancer; 2020 Feb 26; 140():46-54. PubMed ID: 31862577
    [Abstract] [Full Text] [Related]

  • 11. Next generation sequencing in lung cancer: An initial experience from India.
    Gupta P, Saha K, Vinarkar S, Banerjee S, Choudhury SS, Parihar M, Midha D, Mukherjee G, Lingegowda D, Chatterjee S, ArunsinghS M, Shrimali R, Ganguly S, Dabkara D, Biswas B, Mishra DK, Arora N.
    Curr Probl Cancer; 2020 Jun 26; 44(3):100562. PubMed ID: 32178863
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.
    Oncologist; 2016 Jun 26; 21(6):684-91. PubMed ID: 27151654
    [Abstract] [Full Text] [Related]

  • 13. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
    Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB, Gandara DR.
    Cancer; 2020 Jul 15; 126(14):3219-3228. PubMed ID: 32365229
    [Abstract] [Full Text] [Related]

  • 14. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug 15; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 15. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC.
    Clin Lung Cancer; 2020 May 15; 21(3):e191-e204. PubMed ID: 31859066
    [Abstract] [Full Text] [Related]

  • 16. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
    Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A.
    Int J Cancer; 2019 Aug 01; 145(3):649-661. PubMed ID: 30653256
    [Abstract] [Full Text] [Related]

  • 17. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
    Steeghs EMP, Groen HJM, Schuuring E, Aarts MJ, Damhuis RAM, Voorham QJM, PATH consortium, Ligtenberg MJL, Grünberg K.
    Lung Cancer; 2022 May 01; 167():87-97. PubMed ID: 35461050
    [Abstract] [Full Text] [Related]

  • 18. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.
    Clin Cancer Res; 2015 Aug 15; 21(16):3631-9. PubMed ID: 25567908
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ, Carbone DP, D'Souza DM, Shilo K, Abdel-Rasoul M, Zhao W, Williams TM, Jones D, Merritt RE.
    Lung Cancer; 2020 May 15; 143():60-66. PubMed ID: 32208298
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA.
    Clin Lung Cancer; 2021 Jul 15; 22(4):e519-e527. PubMed ID: 33414052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 93.